selected scholarly activity
-
conferences
- Efficacy and safety at 3 and 5 years in the Canadian multicenter, randomized, double-blind trial of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (C-SIRIUS). American Journal of Cardiology. 63L-63L. 2007
- Efficacy and safety at 3 and 5 years in the canadian multi-center, randomized, double-blind trial of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (C-SIRIUS). Canadian Journal of Cardiology. 92C-93C. 2007
- Efficacy and safety at 3 years of the sirolimus-eluting stent to treat de novo long coronary artery lesions in the Canadian multicenter, randomized, double-blind trial C-SIRIUS. Circulation. U714-U714. 2005
- Efficacy and safety at 3 years of the sirolimus-eluting stent for the treatment of patients with long lesions in small vessels from the Canadian multicenter, randomized, double-blind trial C-SIRIUS. American Journal of Cardiology. 53H-54H. 2005
- Randomized comparison of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Journal of the American College of Cardiology. 68A-69A. 2003
- Treatment of no-reflow with the intracoronary administration of the nitric oxide donor nitroprusside: Initial human clinical experience.. American Journal of Cardiology. 5P-5P. 1999
-
journal articles
- In type 2 MI, the T2-risk score predicted death or MI at 1 y. ACP journal club. 176:JC58-JC58. 2023
- In ischemic left ventricular systolic dysfunction, adding PCI to medical therapy did not reduce death or HF hospitalization. ACP journal club. 175:JC135-JC135. 2022
- In ACS with planned invasive evaluation, prasugrel vs ticagrelor reduced a composite of death, MI, or stroke at 1 y. ACP journal club. 172:JC5-JC5. 2020
- In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding. ACP journal club. 172:JC4-JC4. 2020
- After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy. ACP journal club. 167:JC70-JC70. 2017
- The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. Cardiology. 110:271-282. 2008
- Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction. Canadian Journal of Cardiology. 22:131-139. 2006
- A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. American Heart Journal. 151:175.e1-175.e6. 2006
- Influence of education and income on atherogenic risk factor profiles among patients hospitalized with acute myocardial infarction. Canadian Journal of Cardiology. 20:1219-1228. 2004
- The economics of adjunctive therapies in coronary angioplasty: Drugs, devices or both?. Journal of Population Therapeutics and Clinical Pharmacology. 11. 2004
- Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina. Circulation. 108:2439-2445. 2003
- Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary Syndromes. PharmacoEconomics (Auckland). 19:41-55. 2001
- Economic issues in glycoprotein IIb/IIIa receptor therapy. American Heart Journal. 138:s24-s32. 1999